Conclusions
This study suggests that the TBIL, PLT and WT are significantly
associated with voriconazole pharmacokinetic parameters. TBIL is a
critical factor leading to large pharmacokinetic variation of
voriconazole. Using MCS to optimize the dosing regimen in patients with
liver dysfunction based on our PPK model and TBIL stratification we
demonstrated that lower doses and longer administration intervals should
be considered for patients with liver dysfunction.
This is helpful for clinicians
making decisions about voriconazole dosing regimens, especially to
determine efficient initial dosing strategies and in primary hospitals
where TDM is not available.